Long-term Safety Study of Chronocort in the Treatment of Participants With

Status Enrolling by invitation

Clinical Trial Summary

This phase III study is an open-label extension study to be conducted at approximately 21 investigational sites across 3 countries. The study will evaluate the long-term safety and tolerability of Chronocort in participants aged 16 years and over when used as treatment for Congenital Adrenal Hyperplasia (CAH).

Clinical Trial Description

Participants in eligible countries completing one of the specified previous Chronocort studies (DIUR-006 and DIUR 014) can either continue Chronocort treatment (if the participant received Chronocort in the feeder study) or switch to Chronocort treatment (if the participant received standard glucocorticoid therapy in the feeder study) in this open-label extension study. All participants choosing to enter this extension study will have the study procedures fully explained and informed consent obtained, prior to, or at the last visit of the feeder study. Participants who agree to take part in this extension study will then undergo the final visit of the feeder study, with the assessments conducted at the final visit also providing the baseline data for this DIUR-015 extension study where relevant (note participants who are withdrawn from treatment due to titration issues in study DIUR-014 are eligible to enter at the discretion of the Investigator, as long as all DIUR-014 safety assessments and the end of study visit are completed). Once all the baseline assessments are completed, participants will be given sufficient Chronocort to use until the next visit (the study pharmacies will be supplied with Chronocort for dispensing to participants according to the Investigators' instructions). Outcome measures in this study will be assessed versus either the 'initial study baseline' (measurements taken at the start of participation in an interventional Diurnal study, regardless of the treatment assignment in this feeder study) or the protocol-defined 'pre-Chronocort baseline' (measurements taken prior to the first dose of continuous Chronocort). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05299554
Study type	Interventional
Source	Diurnal Limited
Contact
Status	Enrolling by invitation
Phase	Phase 3
Start date	April 1, 2022
Completion date	December 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03687242` - Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia	Phase 2
Active, not recruiting	`NCT04544410` - A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH	Phase 2
Not yet recruiting	`NCT04087148` - Linear Growth of Children With Congenital Adrenal Hyperplasia
Completed	`NCT03162159` - Adult Height Prediction in Congenital Adrenal Hyperplasia
Recruiting	`NCT05687474` - Baby Detect : Genomic Newborn Screening
Enrolling by invitation	`NCT05162950` - Effects and Importance of Epinephrine/Adrenalin Deficiency in CAH
Withdrawn	`NCT03532022` - Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy	Phase 3
Recruiting	`NCT02795871` - Prenatal Dex Study	N/A
Completed	`NCT02934399` - Dynamic Hormone Diagnostics in Endocrine Disease
Recruiting	`NCT04903587` - Gonadal Changes In Congenital Adrenal Hyperplasia Patients
Not yet recruiting	`NCT04536662` - Comparisons of Different Forms of Glucocorticoid on the Recovery of Reproductive Function in Patients With 21α-hydroxylase Deficiency	Phase 4
Recruiting	`NCT04463316` - GROWing Up With Rare GENEtic Syndromes
Active, not recruiting	`NCT04490915` - Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia	Phase 3
Completed	`NCT01807364` - Cardiovascular Risk Profile in Patients With Congenital Adrenal Hyperplasia	N/A
Completed	`NCT02804178` - A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia	Phase 2
Completed	`NCT03019614` - An Open Label Study in Healthy Volunteers to Compare Chronocort® to Hydrocortisone	Phase 1
Not yet recruiting	`NCT04293133` - Final Height in Patients With CAH
Recruiting	`NCT03897504` - Surgical Evaluation of Using the Prepuce in Feminizing Genitoplasty	N/A
Recruiting	`NCT05663320` - A Study of a Virtual Education-Based Transition Intervention to Improve Transition Readiness in Adolescent and Young Adults With Congenital Adrenal Hyperplasia	N/A
Active, not recruiting	`NCT04806451` - Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Patients With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Long-term Safety Study of Chronocort in the Treatment of Participants With Congenital Adrenal Hyperplasia

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms